PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy? (Q72999922)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12586994%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

review article

1 reference

title

PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12586994%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

1 reference

3

A Astrup

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12586994%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

author name string

T M Larsen

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12586994%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

S Toubro

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12586994%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

publication date

1 February 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12586994%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

volume

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12586994%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

page(s)

147-161

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12586994%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12586994%20AND%20SRC:MED&resulttype=core&format=json

Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators

31 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Drug treatment of lipid disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Peroxisome proliferator-activated receptor delta (PPARdelta )-mediated regulation of preadipocyte proliferation and gene expression is dependent on cAMP signaling

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Alterations of peroxisome proliferator-activated receptor delta activity affect fatty acid-controlled adipose differentiation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Activation of PPARdelta alters lipid metabolism in db/db mice.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

PPARgamma knockdown by engineered transcription factors: exogenous PPARgamma2 but not PPARgamma1 reactivates adipogenesis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Regulation of PPAR gamma gene expression by nutrition and obesity in rodents.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Skeletal muscle peroxisome proliferator- activated receptor-gamma expression in obesity and non- insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Distribution of peroxisome proliferator-activated receptors (PPARs) in human skeletal muscle and adipose tissue: relation to insulin action

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Peroxisome proliferator-activated receptor gamma and metabolic disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

A synthetic antagonist for the peroxisome proliferator-activated receptor gamma inhibits adipocyte differentiation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Role of PPARgamma in regulating a cascade expression of cyclin-dependent kinase inhibitors, p18(INK4c) and p21(Waf1/Cip1), during adipogenesis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Hormonal signaling and transcriptional control of adipocyte differentiation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

ADD1/SREBP1 activates PPARgamma through the production of endogenous ligand

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Distinct transcriptional profiles of adipogenesis in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Stage-specific effects of a thiazolidinedione on proliferation, differentiation and PPARgamma mRNA expression in 3T3-L1 adipocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

PPARgamma-dependent and PPARgamma-independent effects on the development of adipose cells from embryonic stem cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Transdifferentiation of myoblasts by the adipogenic transcription factors PPAR gamma and C/EBP alpha

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

PPAR gamma is required for placental, cardiac, and adipose tissue development

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

PPARγ Is Required for the Differentiation of Adipose Tissue In Vivo and In Vitro

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

A dominant-negative peroxisome proliferator-activated receptor gamma (PPARgamma) mutant is a constitutive repressor and inhibits PPARgamma-mediated adipogenesis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor gamma (PPARgamma). Differential activity of PPARgamma1 and -2 isoforms and influence of insulin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Regulation of peroxisome proliferator-activated receptor gamma activity by mitogen-activated protein kinase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Regulation of transcription by AMP-activated protein kinase: phosphorylation of p300 blocks its interaction with nuclear receptors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

PPARgamma activators down-regulate the expression of PPARgamma in 3T3-L1 adipocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Degradation of the peroxisome proliferator-activated receptor gamma is linked to ligand-dependent activation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Depot-specific differences in adipose tissue gene expression in lean and obese subjects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Relationships of PPARγ and PPARγ2 mRNA levels to obesity, diabetes and hyperinsulinaemia in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Up-regulation of peroxisome proliferator-activated receptors (PPAR-alpha) and PPAR-gamma messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-gamma-responsive adipose tissue-specific genes in

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

PPAR-gamma gene expression is elevated in skeletal muscle of obese and type II diabetic subjects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Insulin acutely regulates the expression of the peroxisome proliferator-activated receptor-gamma in human adipocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Developmental and nutritional changes of ob and PPAR gamma 2 gene expression in rat white adipose tissue

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Weight loss reduces expression of SREBP1c/ADD1 and PPARgamma2 in adipose tissue of obese women.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Induction of fatty acid translocase/CD36, peroxisome proliferator-activated receptor-gamma2, leptin, uncoupling proteins 2 and 3, and tumor necrosis factor-alpha gene expression in human subcutaneous fat by lipid infusion

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Pioglitazone-induced increase of insulin sensitivity in the muscles of the obese Zucker fa/fa rat cannot be explained by local adipocyte differentiation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Potentiation of insulin signaling in tissues of Zucker obese rats after acute and long-term treatment with PPARgamma agonists

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Role of fatty acids in the pathogenesis of insulin resistance and NIDDM.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Lipid lowering explains the insulin sensitivity enhancing effects of a thiazolidinedione, 5-(4-(2-(2-phenyl-4-oxazolyl)ethoxy)benzyl)-2,4 thiazolidinedione

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Insulin-sensitizing action of rosiglitazone is enhanced by preventing hyperphagia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Therapeutic index for rosiglitazone in dietary obese rats: separation of efficacy and haemodilution

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Failure of adipocyte differentiation causes type II diabetes mellitus?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Troglitazone action is independent of adipose tissue

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

The Pro12Ala polymorphism in PPAR gamma2 may confer resistance to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Studies of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 (PPAR-gamma2) gene in relation to insulin sensitivity among glucose tolerant caucasians

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Homozygosity of the Pro12Ala variant of the peroxisome proliferation-activated receptor-gamma2 (PPAR-gamma2): divergent modulating effects on body mass index in obese and lean Caucasian men.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-gamma2 gene with obesity in two Caucasian populations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Obesity associated with a mutation in a genetic regulator of adipocyte differentiation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

PPARgamma agonists in type 2 diabetes: how far have we come in 'preventing the inevitable'? A review of the metabolic effects of rosiglitazone

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Diseases of liporegulation: new perspective on obesity and related disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Diabetic KKAy mice exhibit increased hepatic PPARgamma1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical review

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Troglitazone reduces plasma leptin concentration but increases hunger in NIDDM patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Effect of troglitazone on body fat distribution in type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Efficacy of troglitazone on body fat distribution in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Thiazolidinedione derivative improves fat distribution and multiple risk factors in subjects with visceral fat accumulation--double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

The perils of portliness: causes and consequences of visceral adiposity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Differential expression of PPAR gamma1 and gamma2 isoforms in human adipose tissue.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Regional differences in the response of human pre-adipocytes to PPARgamma and RXRalpha agonists

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

The novel hypoglycemic agent YM440 normalizes hyperglycemia without changing body fat weight in diabetic db/db mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.802223

7 January 2021

Identifiers

DOI

10.1038/SJ.IJO.802223

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12586994%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

1 reference